Presenting the Budget in Parliament, Sitharaman said the initiative is aimed at creating a robust ecosystem for biopharma and biosimilars, strengthening domestic capabilities and boosting India’s global competitiveness in high-value pharmaceutical manufacturing

Beyond infrastructure, the industry is seeking stronger public-private collaborations to address the rising prevalence of chronic illnesses